Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Klebsiella pneumoniae lipopolysaccharide (LPS) is a major structural component of the outer membrane of the Gram-negative bacterium Klebsiella pneumoniae, a leading cause of healthcare-associated infections, neonatal sepsis, and multidrug-resistant pneumonia. Structurally, K. pneumoniae LPS consists of three domains: the endotoxic lipid A, a conserved core oligosaccharide, and the highly immunogenic O-antigen (O-polysaccharide). LPS plays a critical role in bacterial virulence and immune evasion by protecting the pathogen from complement-mediated killing and inhibiting host antimicrobial peptides. Because of its abundance and relatively limited serological diversity compared to the capsular polysaccharide, K. pneumoniae LPS is a highly attractive target for novel immunotherapies and vaccines. Therapeutic strategies targeting this molecule include polymyxin antibiotics (such as polymyxin B and colistin), which bind to lipid A to disrupt the bacterial membrane, and bioconjugate vaccines like Kleb4V, which elicit protective antibodies against predominant O-antigen serotypes. Additionally, monoclonal antibodies are being developed to promote opsonophagocytic killing and neutralize endotoxin-mediated inflammatory responses.
Polymyxins bind to the lipid A portion of the lipopolysaccharide, disrupting the outer membrane and causing cell death. Vaccines and monoclonal antibodies target the O-antigen or core-lipid A regions to induce protective humoral immunity, promote opsonophagocytic killing, and neutralize endotoxin activity.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Klebsiella pneumoniae lipopolysaccharide (K. pneumoniae LPS).